Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18591645 | GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIES | February 2024 | March 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18591760 | GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIES | February 2024 | March 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18372823 | ANTIBODY-EVADING VIRUS VECTORS | September 2023 | April 2024 | Allow | 6 | 1 | 1 | No | No |
| 17984045 | DIRECT REPLACEMENT GENOME EDITING | November 2022 | March 2025 | Abandon | 28 | 4 | 0 | Yes | No |
| 17430134 | METHODS AND COMPOSITIONS FOR SELECTING A CANCER TREATMENT IN A SUBJECT SUFFERING FROM CANCER | August 2021 | May 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17355605 | TARGETED INTEGRATION OF NUCLEIC ACIDS | June 2021 | January 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17334345 | METHOD FOR DIAGNOSING DRUG ADDICTION, METHOD FOR SCREENING THERAPEUTIC AGENT FOR DRUG ADDICTION AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DRUG ADDICTION | May 2021 | October 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17294982 | ENHANCED DETECTION OF LOW-COPY-NUMBER NUCLEIC ACIDS IN AN INTEGRATED WORKFLOW | May 2021 | February 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17199173 | SPERM CELL ISOLATION AND SPERM-ASSOCIATED DNA PURIFICATION | March 2021 | February 2025 | Allow | 48 | 4 | 1 | Yes | No |
| 17167991 | METHODS FOR CAPTURE AND ANALYSIS OF MACROMOLECULAR COMPLEXES | February 2021 | July 2024 | Abandon | 42 | 2 | 0 | No | No |
| 16972039 | METHOD OF CHARACTERIZING A POLYNUCLEOTIDE | December 2020 | October 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17250113 | SUPER HLA TYPING METHOD AND KIT THEREOF | November 2020 | February 2024 | Abandon | 39 | 3 | 0 | No | No |
| 17057771 | EPIGENETIC METHOD TO ESTIMATE THE INTRINSIC AGE OF SKIN | November 2020 | July 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17058019 | Enzymatic Enrichment of DNA-Pore-Polymerase Complexes | November 2020 | August 2024 | Abandon | 45 | 3 | 0 | No | No |
| 17054935 | VECTOR INCLUDING A TRANSLATION-IMPAIRED DIHYDROFOLATE REDUCTASE GENE CASSETTE AND UBIQUITOUSLY ACTING CHROMATIN OPENING ELEMENT | November 2020 | May 2023 | Allow | 30 | 1 | 0 | No | No |
| 17053530 | METHOD FOR PRODUCING HOMOZYGOUS CELLS | November 2020 | June 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17053722 | MASSIVELY PARALLEL DISCOVERY METHODS FOR OLIGONUCLEOTIDE THERAPEUTICS | November 2020 | June 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17053336 | QUALITY CONTROL OF LNA OLIGONUCLEOTIDE THERAPEUTICS USING MASSIVELY PARALLEL SEQUENCING | November 2020 | April 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17052624 | PRODUCING RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINS | November 2020 | September 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17086619 | COMPOSITIONS AND KITS FOR RAPID DETECTION SCREENING OF MULTIPLE ANAPLASMA SPECIES AND METHODS OF PRODUCTION AND USE THEREOF | November 2020 | April 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17050052 | SEQUENTIAL PAIRED-END SEQUENCING | October 2020 | July 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17045090 | ANTIBODY-EVADING VIRUS VECTORS | October 2020 | May 2024 | Allow | 43 | 0 | 1 | Yes | No |
| 17039928 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | September 2020 | August 2024 | Abandon | 46 | 1 | 1 | No | No |
| 16966407 | GENE THERAPY FOR LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2C | July 2020 | November 2024 | Allow | 52 | 1 | 1 | Yes | No |
| 16875673 | METHODS FOR EVALUATING LUNG CANCER STATUS | May 2020 | March 2024 | Abandon | 46 | 1 | 1 | No | No |
| 16758694 | Secreted Reporter-Peptides for Optimizing Cell-Based Assays for Analysis on Immuno-Assay Platforms | April 2020 | April 2025 | Allow | 60 | 2 | 0 | No | No |
| 16758844 | NONINVASIVE MOLECULAR CLOCK FOR FETAL DEVELOPMENT PREDICTS GESTATIONAL AGE AND PRETERM DELIVERY | April 2020 | May 2025 | Allow | 60 | 2 | 1 | No | No |
| 16841521 | SYSTEMS AND METHODS FOR RAPID DIAGNOSTIC FOR VARIOUS CANCERS | April 2020 | January 2024 | Abandon | 45 | 3 | 0 | No | No |
| 16807435 | Rapid Display Method in Translational Synthesis of Peptide | March 2020 | January 2024 | Allow | 47 | 2 | 0 | Yes | No |
| 16614878 | SYNTHETIC METHYLOTROPHY | November 2019 | March 2025 | Allow | 60 | 3 | 0 | No | No |
| 16489634 | METHODS AND SYSTEMS FOR PREDICTING TREATMENT RESPONSES IN SUBJECTS | August 2019 | April 2024 | Abandon | 56 | 2 | 1 | No | No |
| 16486287 | GENETICALLY MODIFIED CELL LINES FOR METABOLIC STUDIES | August 2019 | October 2024 | Abandon | 60 | 1 | 1 | No | No |
| 16426374 | RNA BASED BIOMATERIAL FOR TISSUE ENGINEERING APPLICATIONS | May 2019 | October 2024 | Abandon | 60 | 4 | 0 | No | No |
| 16387054 | POLYPEPTIDE EXPRESSION SYSTEMS | April 2019 | August 2023 | Allow | 52 | 1 | 0 | No | No |
| 16111475 | TELOMERASE ENCODING DNA VACCINE | August 2018 | April 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 15999378 | CANCER EPIGENETIC PROFILING | August 2018 | January 2024 | Abandon | 60 | 2 | 1 | No | No |
| 15977565 | Methods for the Treatment of Corneal Dystrophies | May 2018 | March 2023 | Allow | 58 | 4 | 1 | No | No |
| 15920161 | METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNA | March 2018 | July 2023 | Allow | 60 | 7 | 0 | Yes | No |
| 15491125 | SITE-SPECIFIC DNA MODIFICATION USING A DONOR DNA REPAIR TEMPLATE HAVING TANDEM REPEAT SEQUENCES | April 2017 | July 2023 | Allow | 60 | 9 | 1 | Yes | No |
| 14907866 | SELECTION VECTORS AND METHODS OF SELECTING EUKARYOTIC HOST CELLS | January 2016 | August 2023 | Allow | 60 | 8 | 1 | Yes | Yes |
| 14846958 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE EDITING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES | September 2015 | December 2024 | Abandon | 60 | 14 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LINDGREN BALTZEL, MORGAN TAYLOR.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LINDGREN BALTZEL, MORGAN TAYLOR works in Art Unit 1636 and has examined 39 patent applications in our dataset. With an allowance rate of 43.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner LINDGREN BALTZEL, MORGAN TAYLOR's allowance rate of 43.6% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LINDGREN BALTZEL, MORGAN TAYLOR receive 2.49 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by LINDGREN BALTZEL, MORGAN TAYLOR is 46 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +57.4% benefit to allowance rate for applications examined by LINDGREN BALTZEL, MORGAN TAYLOR. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.0% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 38% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.